Literature DB >> 27037817

Population Pharmacokinetics of Dexmedetomidine After Short Intravenous Infusion in Chinese Children.

Hua-Cheng Liu1, Qing-Quan Lian1, Fei-Fei Wu2, Cheng-Yu Wang1, Wei Sun3, Li-Dan Zheng1, Jürgen Schüttler4, Harald Ihmsen5.   

Abstract

BACKGROUND AND
OBJECTIVE: Dexmedetomidine is a highly selective alpha2-adrenoceptor agonist with sedative and analgesic properties which is also used in pediatric anesthesia. Although the pharmacokinetics of dexmedetomidine have been studied in pediatric patients, there are no data for Chinese children available. As alterations in pharmacokinetics due to ethnicity cannot be ruled out, it was the aim of this study to characterize the pharmacokinetics of dexmedetomidine in Chinese pediatric patients.
METHODS: Thirty-nine children aged 1-9 years undergoing surgery were enrolled in the study. Dexmedetomidine was administered as short intravenous infusion of 1-2 µg/kg in 10 min. Venous blood samples were drawn until 480 min after stopping of infusion. Dexmedetomidine plasma concentrations were measured with high-performance liquid chromatography and mass spectrometry. Pharmacokinetic modeling was performed by population analysis using linear compartment models.
RESULTS: Data of 36 patients (age 1-9 years, weight 10-27 kg) were analyzed. The pharmacokinetics of dexmedetomidine were best described by a two-compartment model with an allometric power model and estimates standardized to 70 kg body weight. The population estimates (95 % CI) per 70 kg bodyweight were: clearance 36.2 (33.3-41.1) l/h, central volume of distribution 84.3 (70.3-91.4) l, intercompartmental clearance 82.8 (63.6-136.6) l/h, peripheral volume of distribution 114 (95-149) l, and terminal half-life 4.4 (3.6-5.3) h. Age did not show any influence on weight-adjusted parameters.
CONCLUSIONS: Chinese children showed a similar clearance, but larger volumes of distribution and longer terminal half-life when compared to studies in Caucasians. TRIAL REGISTRATION: ChiCTR-OPC-14005659.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 27037817     DOI: 10.1007/s13318-016-0333-6

Source DB:  PubMed          Journal:  Eur J Drug Metab Pharmacokinet        ISSN: 0378-7966            Impact factor:   2.441


  25 in total

1.  Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs.

Authors:  M A Hughes; P S Glass; J R Jacobs
Journal:  Anesthesiology       Date:  1992-03       Impact factor: 7.892

2.  Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.

Authors:  Radojka M Savic; Mats O Karlsson
Journal:  AAPS J       Date:  2009-08-01       Impact factor: 4.009

Review 3.  Influence of race or ethnicity on pharmacokinetics of drugs.

Authors:  J A Johnson
Journal:  J Pharm Sci       Date:  1997-12       Impact factor: 3.534

4.  Differences in plasma binding of drugs between Caucasians and Chinese subjects.

Authors:  H H Zhou; A Adedoyin; G R Wilkinson
Journal:  Clin Pharmacol Ther       Date:  1990-07       Impact factor: 6.875

Review 5.  Optimal design in pediatric pharmacokinetic and pharmacodynamic clinical studies.

Authors:  Jessica K Roberts; Chris Stockmann; Alfred Balch; Tian Yu; Robert M Ward; Michael G Spigarelli; Catherine M T Sherwin
Journal:  Paediatr Anaesth       Date:  2015-01-09       Impact factor: 2.556

Review 6.  Alpha 2 adrenoceptor agonists and anaesthesia.

Authors:  Y Hayashi; M Maze
Journal:  Br J Anaesth       Date:  1993-07       Impact factor: 9.166

7.  Comparison of haemodynamic changes induced by sevoflurane and halothane in paediatric patients.

Authors:  S Kawana; J Wachi; M Nakayama; A Namiki
Journal:  Can J Anaesth       Date:  1995-07       Impact factor: 5.063

8.  Pharmacokinetics of intravenous dexmedetomidine in children under 11 yr of age.

Authors:  S Vilo; P Rautiainen; K Kaisti; R Aantaa; M Scheinin; T Manner; K T Olkkola
Journal:  Br J Anaesth       Date:  2008-03-31       Impact factor: 9.166

9.  Pharmacokinetics of dexmedetomidine in postsurgical pediatric intensive care unit patients: preliminary study.

Authors:  Susan M Díaz; Alexander Rodarte; Jennifer Foley; Edmund V Capparelli
Journal:  Pediatr Crit Care Med       Date:  2007-09       Impact factor: 3.624

Review 10.  The phenomenon and rationale of marked dependence of drug concentration on blood sampling site. Implications in pharmacokinetics, pharmacodynamics, toxicology and therapeutics (Part I).

Authors:  W L Chiou
Journal:  Clin Pharmacokinet       Date:  1989-09       Impact factor: 6.447

View more
  4 in total

Review 1.  Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine.

Authors:  Maud A S Weerink; Michel M R F Struys; Laura N Hannivoort; Clemens R M Barends; Anthony R Absalom; Pieter Colin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

2.  Population Pharmacokinetics and Pharmacodynamics of Dexmedetomidine in Children Undergoing Ambulatory Surgery.

Authors:  María-Gabriela Pérez-Guillé; Alejandra Toledo-López; Liliana Rivera-Espinosa; Radames Alemon-Medina; Chiharu Murata; Ismael Lares-Asseff; Juan Luis Chávez-Pacheco; Josefina Gómez-Garduño; Ana-Lilia Zamora Gutiérrez; Claudia Orozco-Galicia; Karina Ramírez-Morales; Gustavo Lugo-Goytia
Journal:  Anesth Analg       Date:  2018-09       Impact factor: 5.108

3.  A Population Pharmacokinetic Model of Intravenous Dexmedetomidine for Mechanically Ventilated Children after Neurosurgery.

Authors:  In-Kyung Song; SoJeong Yi; Hyeong-Seok Lim; Ji-Hyun Lee; Eun-Hee Kim; Joo-Youn Cho; Min-Chang Kim; Jin-Tae Kim; Hee-Soo Kim
Journal:  J Clin Med       Date:  2019-10-01       Impact factor: 4.241

4.  Population Modelling of Dexmedetomidine Pharmacokinetics and Haemodynamic Effects After Intravenous and Subcutaneous Administration.

Authors:  Muhammad W Ashraf; Panu Uusalo; Mika Scheinin; Teijo I Saari
Journal:  Clin Pharmacokinet       Date:  2020-11       Impact factor: 6.447

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.